title: Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
authors.forename: Vincent
authors.initials: V
authors.lastname: Sibaud
authors.forename: Florence
authors.initials: F
authors.lastname: Dalenc
authors.forename: Loic
authors.initials: L
authors.lastname: Mourey
authors.forename: Christine
authors.initials: C
authors.lastname: Chevreau
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000068338:Everolimus; D005260:Female; D017789:Granuloma, Pyogenic / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010304:Paronychia / Q000139:chemically induced* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000903:Antibiotics, Antineoplastic; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus